Back to Journals » Infection and Drug Resistance » Volume 11

Extensively drug-resistant Myroides odoratimimus – a case series of urinary tract infections in immunocompromised patients

Authors Licker M, Sorescu T, Rus M, Cirlea N, Horhat F, Jurescu C, Botoca M, Cumpănaș A, Timar R, Muntean D

Received 30 December 2017

Accepted for publication 20 March 2018

Published 18 May 2018 Volume 2018:11 Pages 743—749

DOI https://doi.org/10.2147/IDR.S161069

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Joachim Wink


Monica Licker,1,2 Teodora Sorescu,3,4 Maria Rus,5,6 Natalia Cirlea,6 Florin Horhat,1 Cristiana Jurescu,5,6 Mircea Botoca,7,8 Alin Cumpănas,7,8 Romulus Timar,3,4 Delia Muntean1,2

1Department of Microbiology, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 2Clinical Laboratory, “Pius Brînzeu” Emergency Clinical County Hospital, Timisoara, Romania; 3Department of Internal Medicine II, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 4Diabetes Clinic, “Pius Brînzeu” Emergency Clinical County Hospital, Timisoara, Romania; 5“Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 6“Pius Brînzeu” Emergency Clinical County Hospital, Timisoara, Romania; 7Department of Orthopaedics – Traumatology, Urology and Medical Imaging, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 8Urology Unit, “Pius Brînzeu” Emergency Clinical County Hospital, Timisoara, Romania

Purpose: We report an outbreak of urinary tract infections (UTIs) caused by Myroides odoratimimus, which occurred in the largest clinical hospital in western Romania.
Patients and methods: From June to August 2017, four strains of M. odoratimimus were isolated from the urine samples of patients hospitalized in the urology, diabetes, and surgery departments. Hospital records of all patients whose urine cultures were positive for M. ­odoratimimus were reviewed retrospectively. We also reviewed the cases reported in the literature.
Results: All UTIs, except one, were hospital-acquired infections. All patients with M. odoratimimus UTIs were immunocompromised. Three patients underwent urinary catheterization with a Foley’s catheter upon admission in the emergency department and one presented for replacement of ureterostomy tubes. All Myroides isolates were resistant to almost all the tested antibiotics. Two patients were successfully treated with tigecycline and one was receiving antimicrobial treatment for another infection at the time of isolation of the microorganism.
Conclusion: Although M. odoratimimus is an uncommon pathogen, clinicians should be aware of its ability to cause UTI outbreaks, especially in the immunocompromised population. Due to its multi-drug resistance, it is important to rapidly identify Myroides spp. in order to choose the best treatment regimen.

Keywords: Myroides odoratimimus, urinary tract infection, resistance, outbreak

Introduction

The Myroides genus was created in 19961 for Flavobacterium odoratum species which were excluded from the Flavobacterium genus by Bernardet et al2 due to important genomic and phenotypic differences. The new Myroides genus comprises two species, Myroides odoratus (former F. odoratum) and Myroides odoratimimus, which are Gram-negative rods, strictly aerobic, non-motile, with yellow pigmentation and a characteristic fruity odor.1

Myroides spp. are commonly found in environmental sources, particularly in soil3,4 and water,5,6 but have also been isolated from seafood products,7 meat-processing plants,8 and the gut of adult flesh flies.9

Members of the Myroides genus also behave as low-grade opportunistic pathogens, causing community-10 or hospital-acquired1113 infections. Myroides spp. have been found to be responsible for cases of soft tissue infections,10,14 septic shock and pneumonia,14,15 systemic infections,11,12,16,17 necrotizing fasciitis,18 urinary tract infections (UTIs),19,20 or erysipelas.16

We report an outbreak of UTIs caused by M. odoratimimus in a Romanian hospital, which is, to our knowledge, the first outbreak recorded in our country and the third described in the literature to date.19,20

Patients and methods

Study population

During a 3-month period (from June to August 2017), four isolates of Myroides spp. were identified among the 333 positive urine cultures analyzed in the Microbiology Laboratory of the “Pius Brînzeu” Emergency Clinical County Hospital, Timişoara, Romania. This institution is a 1,173-bed, tertiary care, university-affiliated hospital providing health care services for the western region of Romania. The study was approved by the Hospital Ethics Committee. Patients signed an informed consent upon admission, which included the fact that data recorded during hospitalization could be used for future research studies.

Microbiological analysis and data collection

All isolates were first identified as Myroides spp. using the VITEK® 2 GN ID cards (BioMérieux, Marcy l’Etoile, France) and then confirmed as M. odoratimimus by the matrix assisted laser desorption/ionization-time of flight mass spectrometry (Bruker Daltonics, Bremen, Germany) system.

Antimicrobial susceptibility tests (AST) were performed using the VITEK 2 GN AST-N222 cards by determination of the minimum inhibitory concentration (MIC) and classification into resistance phenotypes. The following antimicrobial agents were tested: ticarcillin, piperacillin, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, amikacin, gentamicin, tobramycin, ciprofloxacin, pefloxacin, minocycline, colistin, and trimethoprim–sulfamethoxazole. MIC results were interpreted according to the Clinical and Laboratory Standards Institute criteria. Extensive drug resistance was defined as acquired resistance to at least one agent in all, but two or fewer antimicrobial categories.21

Hospital records of all patients with positive M. odoratimimus urine cultures were reviewed retrospectively. The collected data included the demographic characteristics of the patients, comorbidities, and the presence of an indwelling urinary catheter. The antimicrobial treatment and the clinical outcomes were individually reviewed.

Results

Four cases of M. odoratimimus-positive urine cultures were identified in the Microbiology Laboratory of the “Pius Brînzeu” Emergency Clinical County Hospital, Timişoara, between June and August 2017. The isolates were recovered from patients admitted to the departments of urology (two cases), surgery (one case), and diabetes (one case), respectively.

Demographics and clinical data of the patients are shown in Table 1. Three (75%) patients were males and one (25%) was a female. The mean age was 56 years (range 36–72). The patient hospitalized in the surgery department (C1) had a case history of kidney transplantation for chronic glomerulonephritis and was under immunosuppressive treatment. He was also suffering from anal condylomatosis, for which he underwent multiple surgical interventions (the last one 4 days before presentation at the emergency room). He was admitted for abdominal pain and anuria. The female patient (C2) had diabetes mellitus and was hospitalized for diabetic ketoacidosis. One of the patients admitted to the urology department (C3) had a case history of transurethral resection of the prostate for benign prostatic hyperplasia and was suffering from COPD, for which he was on long-term corticosteroid treatment; he was admitted for acute urinary retention. The other patient from the urology department (C4) had undergone a radical cystectomy with bilateral cutaneous ureterostomy for a muscle-invasive bladder cancer 3 months earlier. He was admitted for the replacement of the ureterostomy tubes.

Table 1 Clinical characteristics and treatment of the four cases of UTIs due to Myroides odoratimimus

Abbreviations: BNI, bladder neck incision; BPH, benign prostatic hyperplasia; PAD, peripheral artery disease; TUR-P, transurethral resection of prostate; UTI, urinary tract infection.

Three cases (C1–C3) underwent urinary catheterization with a Foley’s catheter on presentation at the emergency room (one for acute urinary retention and two for accurate monitoring of urinary output). These patients also complained of symptoms characteristic of UTI (fever, flank pain, costovertebral angle tenderness, or pelvic discomfort) and their urinalysis showed the presence of nitrites, leukocyte esterase, and more than five white blood cells per high-power field. All these cases were hospital-acquired UTIs, with a mean duration of hospitalization of 11 days (range 2–23) before isolation of the uropathogen.

AST and the determination of MICs revealed that all M. odoratimimus isolates were sensitive only to minocycline and were resistant to beta-lactams (including extended-spectrum cephalosporins and beta-lactamase inhibitors), monobactams, carbapenems, aminoglycosides, fluoroquinolones, polymyxins, and sulfonamides. One isolate demonstrated intermediate susceptibility to piperacillin/tazobactam. MICs of the antimicrobial agents are shown in Table 2.

Table 2 In vitro susceptibility testing of the Myroides odoratimimus isolates

Abbreviations: I, intermediate; MIC, minimum inhibitory concentration; R, resistant; S, susceptible.

Two patients (C2 and C3) received tigecycline for the treatment of UTIs with a good clinical response. One patient (C1) had been receiving antibiotic treatment for a pelvic abscess (with imipenem, amikacin, colistin) for 22 days at the time the microorganism was isolated in urine, with a favorable outcome.

In accordance with the European Association of Urology guidelines,22 C4 did not receive antibiotic treatment as no symptoms were present in this patient.

Discussion

Myroides spp. are Gram-negative bacilli frequently encountered in the environment, usually in sources such as water and soil.36 They are uncommon pathogens in humans, having been reported as causing opportunistic infections, most often in severely immunocompromised hosts.11,2325 Only rarely have they been identified in immunocompetent patients.10,14

The present outbreak of UTIs due to M. odoratimimus is the third described in the literature to date. We reviewed the cases reported in literature to date (Table 3). Holmes et al26 first reported these isolates from UTIs, describing 18 strains of F. odoratum isolated from urine.27 M. odoratimimus has been previously identified as an etiologic agent for UTIs in two nosocomial outbreaks among urologic patients.19,20 Ktari et al19 reported seven cases of UTIs due to M. odoratimimus in the urology unit of a Tunisian hospital, all of them (except one) in patients who underwent endourological surgeries and had urinary calculi. The available clinical data in the Turkish report of Yağci et al20 covering a 3-year period showed that patients with F. odoratum UTIs were catheterized and had either neoplasia of the urinary tract or urinary calculi. In the current report, two of the four patients had urological comorbidities (transurethral resection of the prostate for benign prostatic hyperplasia and cystectomy with bilateral cutaneous ureterostomy for bladder cancer). The four M. odoratimimus cases reported in this study were urinary sources only, although it appears this pathogen may be potentially isolated in other sites. A recently published Indian case report discussed isolating M. odoratimimus from both urine and blood cultures of a patient with anaplastic astrocytoma.28

Table 3 Reported cases of Myroides spp. strains isolated from the urine, as found in the USA National Library of Medicine (PubMed) database (May 12, 2017)

Abbreviations: BPH, benign prostatic hyperplasia; DJ, double-J; ND, not described; UTI, urinary tract infection.

All our patients with M. odoratimimus UTIs had an indwelling urinary device and all except one (C4) have been hospitalized for lengthy periods. The most important predisposing factor for hospital-acquired UTIs is urinary catheterization, which reduces host defense mechanisms and offers easier access of germs to the bladder.29 It is possible that C4 acquired the uropathogen prior to admission, most probably 3 months earlier during his previous hospitalization for radical cystectomy, when he had ureterostomy tubes placed.

We suspect that the current outbreak arose in the emergency room where patients underwent urinary catheterization, although the normal hospital environmental screening did not reveal any contamination with Myroides spp. In many cases, the source of Myroides spp. infection remains unknown, although water in the hospital environment is often suspected of carrying the microorganism.20,30

In the current outbreak, all the patients who developed M. odoratimimus UTIs were immunocompromised. Diabetes mellitus, chronic corticosteroid treatment for COPD, and liver cirrhosis have all been previously identified as causes of immunodepression in patients with Myroides spp. infections.11,2325

Myroides spp. are known to be resistant to a wide range of antimicrobial agents, including beta-lactams, monobactams, carbapenems, and aminoglycosides.27 The resistance to beta-lactams is due to the production of chromosome-encoded metallo-beta-lactamases, TUS-1 for M. odoratus and MUS-1 for M. odoratimimus.13 Due to their multiple antibiotic resistance mechanisms,31 a fast and reliable identification method for Myroides spp. is needed. Schrottner et al showed that the VITEK 2 diagnostic system is suitable for identifying bacteria at the genus level, but cannot differentiate between species. In contrast to this, matrix assisted laser desorption/ionization-time of flight mass spectrometry and 16S rDNA are methods capable of distinguishing between M. odoratus and M. odoratimimus.32

Choosing the appropriate antimicrobial treatment for Myroides infections can be quite challenging because of the limited clinical experience. All M. odoratimimus isolates reported in the present paper were extensive drug resistance strains, sensitive only to minocycline and resistant to all the other tested antimicrobials. Two of our patients were successfully treated with tigecycline. Previous studies reported quinolones combined with rifampicin as optimal therapeutic regimens for treating M. odoratimimus UTI.19 Other sites of Myroides spp. infections benefited from treatment with cotrimoxazole, meropenem, or piperacillin/tazobactam,12,14,17 with favorable clinical responses.

One limitation of the present study could be the lack of pulsed-field gel electrophoresis tests to confirm the outbreak and trace the source of genetically related strains.

Conclusion

Although Myroides spp. are uncommon pathogens, clinicians should be aware of the ability of M. odoratimimus to cause prolonged UTI outbreaks, especially in the immunocompromised population. It is important to identify Myroides spp. infections rapidly in order to choose the best therapeutic regimen, considering the wide range of antibiotic resistance of these microorganisms.

Acknowledgments

We gratefully acknowledge the contribution of Bioclinica Laboratories for Myroides odoratimimus identification on matrix assisted laser desorption/ionization-time of flight mass spectrometry system. Part of this paper was presented at the 10th National Conference of Microbiology and Epidemiology, from Bucharest, Romania, Nov 02–04, 2017.

Disclosure

The authors report no conflicts of interest in this work.

References

1.

Vancanneyt M, Segers P, Torck U, et al. Reclassification of Flavobacterium odoratum (Stutzer 1929) strains to a new genus, Myroides, as Myroides odoratus comb. nov. and Myroides odoratimimus sp nov. Int J Syst Bacteriol. 1996;46(4):926–932.

2.

Bernardet JF, Segers P, Vancanneyt M, Berthe F, Kersters K, Vandamme P. Cutting a Gordian knot: emended classification and description of the genus Flavobacterium, emended description of the family Flavobacteriaceae, and proposal of Flavobacterium hydatis nom. nov. (basonym, Cytophaga aquatilis Strohl and Tait 1978). Int J Syst Bacteriol. 1996;46(1):128–148.

3.

Ram H, Kumar A, Thomas L, Dastager SG, Mawlankar R, Singh VP. Myroides indicus sp. nov., isolated from garden soil. Int J Syst Evol Microbiol. 2015;65(11):4008–4012.

4.

Yang Q, Wang R, Ren S, Szoboszlay M, Moe LA. Practical survey on antibiotic-resistant bacterial communities in livestock manure and manure-amended soil. J Environ Sci Health B. 2016;51(1):14–23.

5.

Vaz-Moreira I, Varela AR, Pereira TV, Fochat RC, Manaia CM. Multidrug resistance in quinolone-resistant gram-negative bacteria isolated from hospital effluent and the municipal wastewater treatment plant. Microb Drug Resist. 2016;22(2):155–163.

6.

Maneerat S, Nitoda T, Kanzaki H, Kawai F. Bile acids are new products of a marine bacterium, Myroides sp. strain SM1. Appl Microbiol Biotechnol. 2005;67(5):679–683.

7.

Morrison BJ, Rubin JE. Carbapenemase producing bacteria in the food supply escaping detection. PLoS One. 2015;10(5):e0126717.

8.

Li L, Ye L, Zhang S, Meng H. Isolation and identification of aerobic bacteria carrying tetracycline and sulfonamide resistance genes obtained from a meat processing plant. J Food Sci. 2016;81(6):M1480–M1484.

9.

Dharne MS, Gupta AK, Rangrez AY, Ghate HV, Patole MS, Shouche YS. Antibacterial activities of multi drug resistant Myroides odoratimimus bacteria isolated from adult flesh flies (Diptera: sarcophagidae) are independent of metallo beta-lactamase gene. Braz J Microbiol. 2008;39(2):397–404.

10.

Maraki S, Sarchianaki E, Barbagadakis S. Myroides odoratimimus soft tissue infection in an immunocompetent child following a pig bite: case report and literature review. Braz J Infect Dis. 2012;16(4):390–392.

11.

Endicott-Yazdani TR, Dhiman N, Benavides R, Spak CW. Myroides odoratimimus bacteremia in a diabetic patient. Proc (Bayl Univ Med Cent). 2015;28(3):342–343.

12.

Elantamilan D, Lyngdoh VW, Choudhury B, Khyriem AB, Rajbongshi J. Septicaemia caused by Myroides spp.: a case report. JMM Case Rep. 2015;2(5):1–4.

13.

Mammeri H, Bellais S, Nordmann P. Chromosome-encoded beta-lactamases TUS-1 and MUS-1 from Myroides odoratus and Myroides odoratimimus (formerly Flavobacterium odoratum), new members of the lineage of molecular subclass B1 metalloenzymes. Antimicrob Agents Chemother. 2002;46(11):3561–3567.

14.

Benedetti P, Rassu M, Pavan G, Sefton A, Pellizzer G. Septic shock, pneumonia, and soft tissue infection due to Myroides odoratimimus: report of a case and review of Myroides infections. Infection. 2011;39(2):161–165.

15.

Lahmer T, Beitz A, Ehmer U, Schmid RM, Huber W. Septic shock due to Myroides odoratus in a medical intensive care unit patient with severe necrotising pancreatitis. Anaesth Intensive Care. 2016;44(2):298–299.

16.

Willems P, Muller J, Verhaegen J, Saegeman V, Desmet S. How to treat a fulminant erysipelas and sepsis caused by Myroides odoratimimus: case report and literature review. Acta Clin Belg. 2017;72(5):331–335.

17.

Beharrysingh R. Myroides bacteremia: a case report and concise review. IDCases. 2017;8:34–36.

18.

Crum-Cianflone NF, Matson RW, Ballon-Landa G. Fatal case of necrotizing fasciitis due to Myroides odoratus. Infection. 2014;42(5):931–935.

19.

Ktari S, Mnif B, Koubaa M, et al. Nosocomial outbreak of Myroides odoratimimus urinary tract infection in a Tunisian hospital. J Hosp Infect. 2012;80(1):77–81.

20.

Yağci A, Cerikçioğlu N, Kaufmann ME, et al. Molecular typing of Myroides odoratimimus (Flavobacterium odoratum) urinary tract infections in a Turkish hospital. Eur J Clin Microbiol Infect Dis. 2000;19(9):731–732.

21.

Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.

22.

Bonkat G, Pickard R, Bartoletti R, et al. Guidelines on urological infections. In: EAU Guidelines. European Association of Urology. 2017. Available from: https://uroweb.org/guideline/urological-infections/. Accessed: September 14, 2017.

23.

Motwai B, Krezolek D, Symeonides S, Khayr W. Myroides odoratum cellulitis and bacteremia: a case report. Infect Dis Clin Pract. 2004;12:343–344.

24.

Bachmeyer C, Entressengle H, Krosrotehrani K, et al. Cellulitis due to Myroides odoratimimus in a patient with alcoholic cirrhosis. Clin Exp Dermatol. 2008;33(1):97–98.

25.

Bachman KH, Sewell DL, Straubaugh LJ. Recurrent cellulitis and bacteremia caused by Flavobacterium odoratum. Clin Infect Dis. 1996;22(6):1112–1113.

26.

Holmes B, Snell JJS, Lapage SP. Revised description from clinical isolates, of Flavobacterium odoratum Stutzer and Kwaschnina 1929, and designation of the neotype strain. Int J Syst Bacteriol. 1977;27(4):330–336.

27.

Holmes B, Snell JJ, Lapage SP. Flavobacterium odoratum: a species resistant to a wide range of antimicrobial agents. J Clin Pathol. 1979;32(1):73–77.

28.

Ranjan M, Karade S, Rahi P, Singh SP, Sen S. Urosepsis due to multi drug resistant Myroides odoratimimus: a case report. Int J Curr Microbiol App Sci. 2017;6(8):1930–1935.

29.

Hooton TM, Bradley SF, Cardenas DD, et al; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–663.

30.

Hugo CJ, Bruun B, Jooste PJ. The genera Empedobacter and Myroides. In: Dworkin M, Fallow S, Rosenberg E, Schleifer KH, Stackebrandt E, editors. The Prokaryotes. New York, NY, USA: Springer; 2006:532–538.

31.

Hu SH, Yuan SX, Qu H, et al. Antibiotic resistance mechanisms of Myroides sp. J Zhejiang Univ Sci B. 2016;17(3):188–199.

32.

Schrottner P, Rudolph WW, Eing BR, Bertram S, Gunzer F. Comparison of VITEK2, MALDI-TOF MS, and 16S rDNA sequencing for identification of Myroides odoratus and Myroides odoratimimus. Diagn Microbiol Infect Dis. 2014;79(2):155–159.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]